Avitar Inc. Signs National Sales Agreement With CITGO
October 11, 2000 09:24:00 AM ET
CANTON, Mass., Oct. 11 /PRNewswire/ -- Avitar, Inc. AVR announced today that it has signed a national sales agreement with the CITGO Petroleum Corporation, if implemented at all of CITGO's locations, that would have a value of $6.5 million annually. Avitar's ORALscreen(TM) and ORALadvantage(TM) products will provide rapid, on-demand, drugs-of-abuse testing for up to 14,500 CITGO brand retail gasoline outlets, convenience stores and Quick Lube outlets.
"Avitar is pleased to enter this agreement with CITGO, as it will allow us to expand our national market presence and bring ORALscreen(TM) into an entirely new industry," said Peter Phildius, Chairman and Chief Executive Officer of Avitar. "We look forward to serving CITGO's employment substance abuse testing needs," added Phildius.
Avitar, Inc. AVR headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreen(TM), the world's first rapid point-of- collection oral fluid test for drugs of abuse, ORALadvantage(TM), the first comprehensive substance abuse program featuring its oral fluid-based products, HAIRscreen(TM), a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices.
For more information, see Avitar's website at www.avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties, including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Tara Wynn
Avitar, Inc.
(781) 821-2440
© 2000 PRNewswire |
